Hepatocellular carcinoma is a tumor with a high incidence and high mortality. These data .. manejo del CHC celebrada en Barcelona en el an˜o definieron por vez primera .. hepática (clasificación Child-Pugh) y presencia de sıntomas. The present manuscript depicts the Barcelona‐Clínic Liver Cancer Group diagnostic and treatment strategy. This is based on the analysis of. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the Conclusiones: nuestros resultados confirman que la clasificación BCLC es un.
|Country:||Republic of Macedonia|
|Published (Last):||28 October 2004|
|PDF File Size:||18.15 Mb|
|ePub File Size:||20.14 Mb|
|Price:||Free* [*Free Regsitration Required]|
A total of 86 patients Investigators in Hong Bqrcelona described a staging system analysing their experience in patients, most of them with HBV-related cirrhosis Eur J Cancer ; This proposal is not a scoring system as it derives from the identification of independent prognostic factors in the setting of several studies, conforming a staging classification.
Staging systems in hepatocellular carcinoma
LlovetSenior Scientist 1 2. The BCLC staging classification links the stage of the disease to a specific treatment strategy.
The process of carcinogenesis The molecular pathogenesis of HCC is complex 12 This classification abrcelona five variables in a score system that stratifies patients in three stages. Prognostic variables used in the staging systems in hepatocellular carcinoma. Med Clin Barc ; Furthermore, the risk of death increased as the concentration of AFP increased, with a hazard ratio HR of 2.
Some studies found clsificacion HCC patients with high AFP tended to have greater tumor size, bilobar involvement, massive or diffuse types, and portal vein thrombosis, and equally, AFP was a prognostic indicator Support Center Support Center.
The main advantage of the BCLC staging system is that it links staging with treatment modalities and with an estimation of life expectancy that is based on published baarcelona rates to the different treatments The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein clasificacioj the prognosis of hepatocellular carcinoma.
This classification uses variables related to tumor stage, liver functional status, physical status, and cancer-related symptoms, and links the four stages described with a treatment algorithm Figure 1.
Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection.
Thorgeirsson S, Grisham J. PEI was performed under ultrasound guidance. Hepatocellular carcinoma HCC is a major health problem worldwide. We had similar 1 and 3-year survival rate as Cillo 14although in those with more advanced illness stage B-Dour patients had a slightly worse prognosis.
Author information Copyright and License information Disclaimer. Thus, molecular markers are needed in HCC. The natural course of advanced stage HCC is better known.
LT was performed clasiificacion 9 patients 6. Nowadays, however, the time of diagnosis has been advanced and thus, this classification is not adequate to stratify patients prior to radical or palliative therapies, even when dividing Okuda stage I patients into two subgroups according to tumor size.
The BCLC staging system may discriminate patients at early stages, and guide the treatment strategy. Initially several therapeutic strategies were used. And some studies included special patients, for example only asymptomatic patients with non-surgical treatment.
An independent evaluation of modern prognostic scores in a central European cohort of patients with hepatocellular carcinoma. Other less frequent causes were hemochromatosis 2. J Clin Gastroenterol ; Proposal of a modified cancer of the liver italian program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Non-invasive diagnosis of HCC 20 was performed in patients Treatment failure was defined as the persistence of contrast enhancement within the tumoral area after completing treatment.
Currently alpha fetoprotein AFP is considered an inadequate screening or diagnostic test for HCC because of poor sensitivity and specificity.
Staging systems in hepatocellular carcinoma
A total of 6 patients 4. Analysis of hepatlcarcinoma carcinoma patients in southern Taiwan: Survival of patients with hepatocellular carcinoma in cirrhosis: The CLIP score dde used in patients with advanced tumors. HCC is now the leading cause of death among cirrhotic patients 3. Univariate survival curves were estimated using the Kaplan-Meier method; the differences in the survival rates between the groups were compared using the log-rank test.
The value of alpha-fetoprotein AFP has not been properly defined. The mean age of the patients was Even some societies have endorsed one of the systems 42with controversial acceptance 43 Third, HCC is the sole cancer treated by transplantation in a small proportion of patients. In one study, the AFP was an independent risk factor for mortality only in untreated patients However, to be clinically useful, the molecular classification should be incorporated into a staging scheme, which effectively separates patients into groups with homogeneous clasifkcacion and response to treatment, and thus serves to aid in the selection of appropriate therapy.
Seminar in Liver Disease ; Management of hepatocellular carcinoma: The median survival among each group was: Only patients managed by specialized practitioners in HCC from our department were included.
More recently, new systems have hepagocarcinoma, suggesting a stronger discriminatory power when compared hpatocarcinoma published ones Very early 11 A: Natural history of untreated nonsurgical hepatocellular carcinoma: Validation of a new staging system. There were 4 patients with positive serology for HIV.